Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Re
Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
Can Anything Derail Salix Pharmaceuticals?
Expanded labeling for the sub-q form of Relistor could add $100 million in revenue, but doesn't change the business to a large extent
Why GW Pharmaceuticals Could be the Next Marijuana Bubble Stock to Pop
Shares of GW Pharmaceuticals have more than doubled in the last year.
This Week in Biotech: Actions Speak Louder Than Words
Regulatory actions provided the impetus to big moves for these five biotech stocks.